ArticleAmerican heart journal2017
Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort.
Article in American heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Brain-Derived Neurotrophic Factor in Acute Coronary Syndromes: Beyond Diagnosis Toward Biological Phenotyping and Risk Stratification.International journal of molecular sciences · 2026Review
- Childhood trauma is associated with perceived stress and hair cortisol levels characterized by the BDNF Val66Met genotype and sex.Frontiers in psychiatry · 2025Article
- A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy.Frontiers in nutrition · 2025Article
- The intriguing role of platelets as custodians of brain-derived neurotrophic factor.Research and practice in thrombosis and haemostasis · 2024Article
- Brain-derived neurotrophic factor associated with kidney function.Diabetology & metabolic syndrome · 2023Article
- Brain-derived neurotrophic factor rs6265 (Val66Met) single nucleotide polymorphism as a master modifier of human pathophysiology.Neural regeneration research · 2023Review
- Sex-Based Differences in Cardiac Gene Expression and Function in BDNF Val66Met Mice.International journal of molecular sciences · 2021Article
- REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.Frontiers in pharmacology · 2021Article
- Associations of the BDNF Val66Met Polymorphism With Body Composition, Cardiometabolic Risk Factors, and Energy Intake in Youth With Obesity: Findings From the HEARTY Study.Frontiers in neuroscience · 2021Article
- Article
- The BDNF rs6265 Polymorphism is a Modifier of Cardiomyocyte Contractility and Dilated Cardiomyopathy.International journal of molecular sciences · 2020Article
- Association between BDNF rs6265 polymorphisms and postoperative cognitive dysfunction in Chinese Han Population.Brain and behavior · 2020Article
- Impact ofCells · 2020Article
- Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure.Stress (Amsterdam, Netherlands) · 2019Review
- The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- Interaction between BDNF val66met polymorphism and personality on long-term cardiac outcomes in patients with acute coronary syndrome.PloS one · 2019Article
- Mechanisms supporting potential use of bone marrow-derived mesenchymal stem cells in psychocardiology.American journal of translational research · 2019Review
- BDNF Actions in the Cardiovascular System: Roles in Development, Adulthood and Response to Injury.Frontiers in physiology · 2019Review
- An Integrative Review of Brain-Derived Neurotrophic Factor and Serious Cardiovascular Conditions.Nursing researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe rs6265 (Val66Met) single-nucleotide polymorphism in the BDNF gene has been related to a number of endophenotypes that have in turn been shown to confer risk for atherosclerotic cardiovascular disease (CVD). To date, however, very few studies have examined the association of the Val66Met single-nucleotide polymorphism with CVD clinical outcomes.
methodsIn a cohort of 5,510 Caucasian patients enrolled in the CATHeterization GENetics (CATHGEN) study at Duke University Hospital between 2001 and 2011, we determined the severity of coronary artery disease (CAD) and CVD event incidence through up to 11.8years of follow-up. We examined the association of Val66Met genotype with time-to-death or myocardial infarction, adjusting for age, sex, CAD risk variables, and CAD severity measures.
resultsThe Val/Val genotype was associated with a higher risk than Met carriers for clinical CVD events (P=.034, hazard ratio 1.12, 95% CI 1.01-1.24). In addition, compared with Met carriers, individuals with the Val/Val genotype had a greater odds of having more diseased vessels (odds ratio 1.17, 95% CI 1.06-1.30, P=.002), and lower left ventricular ejection fraction (β=-0.72, 95% CI, -1.42 to -0.02, P=.044).
conclusionsThe Val/Val genotype was associated with greater severity of CAD and incidence of CVD-related clinical events in a patient sample. If these findings are confirmed in further research, intervention studies in clinical groups with the Val/Val genotype could be undertaken to prevent disease and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.